FEPROSIDNINE, also known as Sidnofen, is a psychostimulant and monoamine oxidase inhibitor developed in USSR.

Bromerguride is an ergot derivative with dopamine antagonistic activity. Bromerguride has been claimed to bind to 5-HT1A receptors and to have 5-HT agonist properties. The neuropharmacological effects caused by the drug in animals were characterized by a central depressant neuroleptic-like symptomatology; the neuroleptic activity of the Bromerguride being at least in the same order of magnitude as haloperidol.

Ertiprotafib was originally developed as an inhibitor of PTP1B. Multiple targets of ertiprotafib, in addition to PTP1B inhibition, have been suggested including dual PPARalpha/PPARgamma agonism and IKK-beta inhibition. It normalized the plasma glucose and insulin levels in diabetic animal models and progressed to a phase II clinical trial for the treatment of Type 2 diabetes mellitus. Ertiprotafib development has been discontinued.

Dimetamfetamine is the N-methylated analog of methamphetamine, produces behavioral effects that are generally comparable to those of methamphetamine, but with reduced potency. It is often found as an impurity in preparations of methamphetamine. Dimetamfetamine itself is less neurotoxic than methamphetamine. Dimetamfetamine is metabolized to p-hydroxyl methamphetamine, p-hydroxyl dimetamfetamine, amphetamine, methamphetamine, and N,N-dimethylamphetamine N-oxide in humans, and flavin-containing monooxygenase-1 and CYP2D6 are mainly involved in the N-oxidation and N-demethylation of dimetamfetamine, respectively. Dimetamfetamine has also been used illegally in Korea, and the Korean government placed DMA on the official list of controlled substances on December 4, 2006.

LAROTAXEL is a taxoid with potential antineoplastic activity. It prevents microtubule depolymerization, thereby inhibiting cell proliferation. It displays a broad spectrum of antitumor activity in vitro and in vivo, including activity against P-glycoprotein expressing tumors. LAROTAXEL was in phase III clinical trials for the treatment of breast cancer, pancreatic cancer, and bladder cancer. However, its development was discontinued.

Halocortolone, a synthetic glucocorticoid that was used as a vasoconstrictor, but was never marketed

Mavatrep (JNJ-39439335) is a TRPV1 antagonist. It exerts analgesic potential. Mavatrep demonstrated sustained pharmacodynamic effects (heat pain perception, heat pain latency, capsaicin-induced flare), and an efficacy signal in participants with osteoarthritis

Propenzolate is a pyridine derivative patented by National Research Development Corp. as an anticholinergic agent. Propenzolate is effective antidotes to the cholinesterase-inhibiting action of various organophosphorus compounds. In clinical trials, Propenzolate has an activity that decreases to some extent the secretion of hydrochloric acid and the volume of gastric juice. Adverse effects, including nausea, vomiting, weakness, and drowsiness, as well as xerostomia and cycloplegia, are observed in a high percentage of patients receiving 0.5 to 1.0 mg. every 12 hours.

Podilfen is the vasodilator. It was used as an antihypertensive agent.